
CLAIMS

1. A compound according to Formula I, or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 is C_{1-4}alkylene-R^4;

R^2 is selected from CO_2H and tetrazolyl;

R^3 is selected from hydrogen and methyl;

X is CR^5R^6 or O;

R^4 is 1,2,3-triazolyl, 1,2,4-triazolyl or pyrimidinyl, wherein said triazolyl or pyrimidinyl group is:

optionally substituted with one or more substituents independently selected from C_{1-4}alkyl, C_{1-3}haloalkyl, C_{3-7}cycloalkyl, C_{1-4}alkylene-C_{3-7}cycloalkyl, halo, OH, C_{1-3}alkoxy, and cyano; and

optionally fused to a cycloalkyl or heterocyclyl ring;

R^5 is selected from hydrogen, C_{1-4}alkyl, C_{3-7}cycloalkyl and C_{1-3}haloalkyl; and

R^6 is selected from hydrogen and C_{1-4}alkyl; or

R^5 and R^6, together with the carbon atom to which they are attached, form a 3- or 4-membered cycloalkyl ring;

m is 0 or 1; and

n is 1 or 2;


provided that the compound of formula I is not one of the following compounds:


(1*S*,2*R*)-2-((*S*)-5-chloro-8-((1,5-dimethyl-1*H*-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid;


(1*S*,2*R*)-2-((*S*)-5-chloro-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-*a*]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid;


(1*S*,2*R*)-2-((*S*)-5-chloro-8-((5,6-dihydro-4*H*-pyrrolo[1,2-*c*][1,2,3]triazol-3-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid;
(1*S*,2*R*)-2-((*S*)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1*H*-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; or
(1*S*,2*R*)-2-((*S*)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1*H*-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid.


2. A compound according to claim 1, wherein said compound has one of the structural formulae IA to IK shown below:



(IA)



(IB)



(IC)



(ID)



(IE)


(IF)


(IG)


(IH)


(IJ)


(IK)

wherein R^1 to R^6, X and m are as defined in claim 1.

3. A compound according to claim 1 or claim 2, wherein R^1 is CH_2-R^4.

4. A compound according to any one of claims 1 to 3, wherein R^2 is CO_2H.


5. A compound according to any one of claims 1 to 4, wherein R^3 is methyl.

6. A compound according to any one of claims 1 to 5, wherein R^4 is 1,2,3-triazolyl optionally substituted with one or more substituents independently selected from C_{1-4}alkyl, C_{1-3}haloalkyl, C_{3-7}cycloalkyl and C_{1-4}alkylene-C_{3-7}cycloalkyl.

7. A compound according to any one of claims 1 to 5, wherein R^4 is 1,2,4-triazolyl optionally substituted with one or more substituents independently selected from C_{1-4}alkyl, C_{1-3}haloalkyl, C_{3-7}cycloalkyl and C_{1-4}alkylene-C_{3-7}cycloalkyl.


8. A compound according to any one of claims 1 to 5, wherein R^4 is pyrimidinyl optionally substituted with one or more substituents independently selected from C_{1-4}alkyl and C_{1-3}haloalkyl.

9. A compound according to any one of claims 1 to 5, wherein R^4 is selected from one of the following groups:



wherein said group is optionally substituted with C_{1-4}alkyl and C_{1-3}fluoroalkyl.

10. A compound according to any one of claims 1 to 5, wherein R^4 is selected from one of the following groups:




11. A compound according to any one of claims 1 to 10, wherein X is CR^5R^6.

12. A compound according to any one of claims 1 to 11, wherein R^5 is methyl and R^6 is hydrogen.

13. A compound according to any one of claims 1 to 11, wherein R^5 and R^6, together with the carbon atom to which they are attached, form a cyclopropyl ring.

14. A compound according to any one of claims 1 to 13, wherein m is 1.

15. A compound according to claim 1, wherein said compound has the structural formula IL shown below, or a pharmaceutically acceptable salt thereof:



(IL)

wherein R^5 and R^6 are as defined in claim 1 and R^7 and R^8 are independently selected from hydrogen, C_{1-4}alkyl, C_{1-3}haloalkyl, C_{3-7}cycloalkyl, C_{1-4}alkylene-C_{3-7}cycloalkyl, halo, OH, C_{1-3}alkoxy and cyano; or R^7 and R^8, taken together with the atoms to which they are attached, form a 5- or 6-membered heterocyclyl ring.

16. A compound according to claim 15, wherein R^5 is methyl and R^6 is hydrogen.

17. A compound according to claim 15, wherein R^5 and R^6, together with the carbon atom to which they are attached, form a cyclopropyl ring.

18. A compound according to any one of claims 15 to 17, wherein R^7 is methyl and R^8 is hydrogen, methyl, or difluoromethyl.

19. A compound according to claim 1, which is selected from:
5-(((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-2-((1R,2S)-2-methyl-2-(1H-tetrazol-5-yl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-5-azaspiro[2.4]heptan-6-one;
(1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((3-oxomorpholino)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid;

(1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid;
(1S,2R)-2-((S)-5-chloro-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid;
(1S,2R)-2-((S)-5-chloro-8-((4,5-dimethyl-4H-1,2,4-triazol-3-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid;
(1S,2R)-2-((S)-5-chloro-7-fluoro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; and
(1*S*,2*R*)-2-((S)-5-chloro-7-fluoro-8-((5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid;
or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition comprising a compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

21. A compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 20, for use in therapy.

22. A compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 20, for use in the treatment of diseases or disorders mediated by Nrf2 activation.

23. A compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 20, for use in the treatment of chronic obstructive pulmonary disease, acute, chronic and severe asthma, acute lung injury/acute respiratory distress syndrome with or without accompanying multi organ dysfunction syndrome, pulmonary fibrosis including idiopathic pulmonary fibrosis, cystic fibrosis, COVID-19, diabetes, atherosclerosis, hypertension, heart failure, myocardial infarction and repair, cardiac remodelling, cardiac arrhythmias, cardiac hypertrophy, heart failure with preserved ejection fraction, diabetic cardiomyopathy, sarcopenia, obesity, metabolic syndrome,

diabetes mellitus, insulin resistance, pulmonary arterial hypertension, subarachnoid haemorrhage, intracerebral haemorrhage, ischemic stroke, beta-thalassemia, sickle cell disease, rheumatoid arthritis, irritable bowel disorder, ulcerative colitis, Crohn's disease, psoriasis, radiation-induced dermatitis, atopic dermatitis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, toxin-induced liver disease, viral hepatitis and cirrhosis, chronic kidney disease, diabetic nephropathy, autosomal dominant polycystic kidney disease, CKD associated with type 1 diabetes (T1D), IgA nephropathy (IgAN), Alport Syndrome, focal segmental glomerulosclerosis, Huntington's disease, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, frontotemporal dementia, multiple sclerosis, Friedreich's ataxia, chronic pain, schizophrenia, lung cancer, breast cancer, colon cancer, age related macular degeneration (AMD), Fuchs Endothelial Corneal Dystrophy, uveitis or preeclampsia.

24. A method of treating a disease or disorder selected from chronic obstructive pulmonary disease, acute, chronic and severe asthma, acute lung injury/acute respiratory distress syndrome with or without accompanying multi organ dysfunction syndrome, pulmonary fibrosis including idiopathic pulmonary fibrosis, cystic fibrosis, COVID-19, diabetes, atherosclerosis, hypertension, heart failure, myocardial infarction and repair, cardiac remodelling, cardiac arrhythmias, cardiac hypertrophy, heart failure with preserved ejection fraction, diabetic cardiomyopathy, sarcopenia, obesity, metabolic syndrome, diabetes mellitus, insulin resistance, pulmonary arterial hypertension, subarachnoid haemorrhage, intracerebral haemorrhage, ischemic stroke, beta-thalassemia, sickle cell disease, rheumatoid arthritis, irritable bowel disorder, ulcerative colitis, Crohn's disease, psoriasis, radiation-induced dermatitis, atopic dermatitis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, toxin-induced liver disease, viral hepatitis and cirrhosis, chronic kidney disease, diabetic nephropathy, autosomal dominant polycystic kidney disease, CKD associated with type 1 diabetes (T1D), IgA nephropathy (IgAN), Alport Syndrome, focal segmental glomerulosclerosis, Huntington's disease, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, frontotemporal dementia, multiple sclerosis, Friedreich's ataxia, chronic pain, schizophrenia, lung cancer, breast cancer, colon cancer, age related macular degeneration (AMD), Fuchs Endothelial Corneal Dystrophy, uveitis and preeclampsia, said method comprising administering to a subject in need of such a treatment a therapeutically effective amount of a compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof.